Get started
Author

Seneca S. Kinn-Gurzo

Observed names: Seneca Kinn-Gurzo, Seneca Kinn‐Gurzo
ORCID: 0009-0004-0407-9788
Observed ORCID: 0009-0004-0407-9788
OpenAlex ID: A5029155666
Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al. · Clinical Cancer Research · 13
Microplastics impede larval urchin selective feeding
2022 · Pui Lam Ng, Seneca S. Kinn-Gurzo, et al. · The Science of The Total Environment · 11
Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene
2025 · Florian Henning Geyer, Alina Ritter, et al. · 癌症：英文版 · 10
Resilience of invasive tubeworm (Hydroides dirampha) to warming and salinity stress and its implications for biofouling community dynamics
2020 · Ting-Xuan Liu, Seneca Kinn-Gurzo, et al. · Marine Biology · 6
Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcription
2026 · Rebecca Kaufman, Guillermo Flores, et al. · Nature Communications · 2
Abstract 635: Defining the intertumoral and intratumoral transcriptional heterogeneity of EWS::FLI1 in Ewing sarcoma.
2026 · Rachael Hinshaw, Zachary P. Tolstyka, et al. · Cancer Research
Supplementary Table S2 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
Supplementary Table S1 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
Data from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
Supplementary Table S3 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
Supplementary Table S3 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
PDF
Supplementary Figures S1-S15 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
Data from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
Supplementary Figures S1-S15 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
Supplementary Table S2 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
Supplementary Table S1 from Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma
2024 · Jennifer Jess, Katie M. Sorensen, et al.
Super-enhancer-driven CACNA2D2 is an EWSR1::WT1 signature gene encoding a diagnostic marker for desmoplastic small round cell tumor (DSRCT)
2024 · Florian H. Geyer, Alina Ritter, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract 1081: A role for the oncogenic driver fusion protein EWS-FLI1 in the targeting of DR5 by INBRX-109 in Ewing sarcoma
2024 · Curtis C. Parker, Lauren M. Gaetano, et al. · Cancer Research
Abstract 1466: Heterogeneity of the EWS-FLI1 transcriptome drives differences in the cellular phenotype of Ewing sarcoma cell lines
2023 · Seneca S. Kinn-Gurzo, Susan M. Kitchen-Goosen, et al. · Cancer Research
Works count: 19
Citation count: 42
H-index: 4
I10-index: 3
Year
Topic
Type